The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO GI 2021 | Highlights in HCC from ASCO GI 2021

Name: Highlights in HCC from ASCO GI 2021
Uploaded: 2021-01-20T00:00:00Z
Duration: 3 min 5 s
Description: Jean-Luc Van Laethem, MD, PhD, Erasme Hospital University, Brussels, Belgium, outlines updates in hepatocellular carcinoma (HCC), including results from the IMBrave study, as well as the use of systemic therapies in combination with localized approaches. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Jean-Luc Van Laethem • 20 Jan 2021

ASCO GI 2021

Gastrointestinal Cancer Liver Cancer Pembrolizumab Sorafenib

Jean-Luc Van Laethem, MD, PhD, Erasme Hospital University, Brussels, Belgium, outlines updates in hepatocellular carcinoma (HCC), including results from the IMBrave study, as well as the use of systemic therapies in combination with localized approaches. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).